ZURICH: Swiss-listed drugmaker Newron must delay a trial of its prospective schizophrenia medicine evenamide after the U.S. Food and Drug Administration raised concerns about central nervous system (CNS) events that have emerged in rats and dogs. The company, whose Xadago against Parkinson's ...
from Latest News http://bit.ly/2JHGyr3
Newron delays schizophrenia drug trial after FDA raises concerns
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment